Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Multicenter, Multiple-dose Study of ALX-0171 Versus Placebo Along With Standard of Care in Japanese Infants and Young Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection
Conditions
Interventions
ALX-0171 1.5 mg/kg
Placebo
Locations
25
Japan
Investigator Site
Aoi-ku, Japan
Investigator Site
Asahikawa, Japan
Investigator Site
Fuchu-shi, Japan
Investigator site
Fukuyama-shi, Japan
Investigator Site
Funabashi, Japan
Investigator site
Gifu, Japan
Start Date
March 1, 2018
Primary Completion Date
October 24, 2018
Completion Date
October 24, 2018
Last Updated
July 30, 2019
Lead Sponsor
Ablynx, a Sanofi company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions